Mesenchymal Stem Cell Transplantation Reverses Multiorgan Dysfunction in Systemic Lupus Erythematosus Mice and Humans
Top Cited Papers
Open Access
- 19 March 2009
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 27 (6), 1421-1432
- https://doi.org/10.1002/stem.68
Abstract
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that, despite the advances in immunosuppressive medical therapies, remains potentially fatal in some patients, especially in treatment‐refractory patients. Here, we reported that impairment of bone marrow mesenchymal stem cells (BMMSCs) and their associated osteoblastic niche deficiency contribute in part to the pathogenesis of SLE‐like disease in MRL/lpr mice. Interestingly, allogenic BMMSC transplantation (MSCT) is capable of reconstructing the bone marrow osteoblastic niche and more effectively reverses multiorgan dysfunction when compared with medical immunosuppression with cyclophosphamide (CTX). At the cellular level, MSCT, not CTX treatment, was capable to induce osteoblastic niche reconstruction, possibly contributing to the recovery of regulatory T‐cells and reestablishment of the immune homeostasis. On the basis of the promising clinical outcomes in SLE mice, we treated four CTX/glucocorticoid treatment‐refractory SLE patients using allogenic MSCT and showed a stable 12–18 months disease remission in all treated patients. The patients benefited an amelioration of disease activity, improvement in serologic markers and renal function. These early evidences suggest that allogenic MSCT may be a feasible and safe salvage therapy in refractory SLE patients. STEM CELLS 2009;27:1421–1432Keywords
Funding Information
- California Institute for Regenerative Medicine (RN1-00572)
- NIDCR/NIH (R01DE017449, R21 DE017632)
- National Natural Science Foundation of China (30772014)
- Chinese Education Ministry (20050315001)
- Jiangsu Province 135 Talent Foundation (RC2007002)
This publication has 52 references indexed in Scilit:
- Peripheral B cell abnormalities and disease activity in systemic lupus erythematosusLupus, 2008
- Pharmacologic Stem Cell Based Intervention as a New Approach to Osteoporosis Treatment in RodentsPLOS ONE, 2008
- T-regulatory cells in systemic lupus erythematosusLupus, 2008
- Novel molecular targets in the treatment of systemic lupus erythematosusAutoimmunity Reviews, 2008
- Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategyExpert Opinion on Investigational Drugs, 2007
- Reversal of autoimmune disease in lupus-prone New Zealand black/New Zealand white mice by nonmyeloablative transplantation of purified allogeneic hematopoietic stem cellsBlood, 2007
- Abnormal surface markers expression on bone marrow CD34+ cells and correlation with disease activity in patients with systemic lupus erythematosusClinical Rheumatology, 2007
- Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destructionThe Journal of Experimental Medicine, 2006
- Therapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosusNature Clinical Practice Rheumatology, 2006
- Osteoblastic cells regulate the haematopoietic stem cell nicheNature, 2003